Workflow
Durasert®
icon
Search documents
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire News Room· 2025-06-16 11:00
About EyePoint EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining ...